Docking‐Based Virtual Screening Identifies a Small‐Molecule Inhibitor of the Translesion Synthesis REV7/REV3 Protein–Protein Interaction
ChemMedChem · 2026
DOI: 10.1002/cmdc.70427 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Noah J Harrahill and 10 co-authors. Institution: Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, USA. Major MEDLINE topics: Molecular Docking Simulation, DNA-Directed DNA Polymerase, Mad2 Proteins, Small Molecule Libraries. Cited 1 times so far (Crossref); 69 references. The full text is freely available in PubMed Central. Funded by: NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Abstract (original language)
REV7 is an adaptor protein that mediates protein–protein interactions (PPIs) in DNA damage response and cell cycle control. REV7 functions as a subunit of the translesion synthesis (TLS) DNA polymerase POLζ, which is involved in the replicative bypass of DNA lesions. REV7 is also a component of the shieldin complex, which mediates the choice of pathway for DNA double‐stranded break (DSB) repair. TLS promotes cancer cell survival after DNA damage and serves as a mechanism through which cancers develop acquired chemoresistance. DSB repair helps cancers mitigate DNA breaks induced by radiation; therefore, inhibition of REV7 PPIs has emerged as a therapeutic strategy. We performed a docking‐based virtual screen to identify compounds predicted to disrupt PPIs between REV7 and the REV7‐binding motifs (RBMs) found in the REV3 subunit of POLζ (TLS) and the SHLD3 subunit of shieldin (DSB repair). Biochemical analysis of a promising hit compound and several analogues demonstrated the ability of this scaffold to disrupt the REV7/RBM REV3 PPI. Several REV7 inhibitors sensitize human cancer cells to radiation treatment, identifying these compounds as a new class of TLS and DSB‐repair targeted anticancer drugs with potential as adjuvant therapies to improve the efficacy of genotoxic cancer therapies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, USA.
- University of Vermont Cancer Center and Department of Microbiology and Molecular Genetics, University of Vermont, Burlington, Vermont, USA.
- Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, Connecticut, USA.
ORCID profiles: Noah J Harrahill, Radha Charan Dash, Vihit Gupta, Dane H Geddes-Buehre, Colin Brereton, Nimrat Chatterjee, Dmitry M Korzhnev, M Kyle Hadden
Funding
- NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
Cite
APA
Harrahill, N. J., Patel, S. M., Dash, R. C., Zaino, A. M., Gupta, V., Geddes-Buehre, D. H., Brereton, C., Rizzo, A. A., Chatterjee, N., Korzhnev, D. M., & Hadden, M. K. (2026). Docking‐Based Virtual Screening Identifies a Small‐Molecule Inhibitor of the Translesion Synthesis REV7/REV3 Protein–Protein Interaction. ChemMedChem. https://doi.org/10.1002/cmdc.70427
Vancouver
Harrahill NJ, Patel SM, Dash RC, Zaino AM, Gupta V, Geddes-Buehre DH, et al. Docking‐Based Virtual Screening Identifies a Small‐Molecule Inhibitor of the Translesion Synthesis REV7/REV3 Protein–Protein Interaction. ChemMedChem. 2026. doi:10.1002/cmdc.70427
BibTeX
@article{Harrahill2026,
author = {Harrahill, Noah J and Patel, Seema M and Dash, Radha Charan and Zaino, Angela M and Gupta, Vihit and Geddes-Buehre, Dane H and Brereton, Colin and Rizzo, Alessandro A and Chatterjee, Nimrat and Korzhnev, Dmitry M and Hadden, M Kyle},
title = {Docking‐Based Virtual Screening Identifies a Small‐Molecule Inhibitor of the Translesion Synthesis REV7/REV3 Protein–Protein Interaction},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70427}
}
EUVIMED